Drug Trial Radar · NCT01797445
Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Last checked: Nov 19, 2026Latest source record: Mar 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
872
Actual
Start
Mar 12, 2013
Primary completion
Sep 19, 2014
Study completion Oct 3, 2018
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Feb 22, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) in HIV-1 positive, antiretroviral treatment-naive adults.
Conditions
- HIV
- HIV Infections
Interventions
E/C/F/TAFDrug
150/150/200/10 mg FDC tablet administered orally once daily
E/C/F/TDFDrug
150/150/200/300 mg FDC tablet administered orally once daily
E/C/F/TDF PlaceboDrug
Tablet administered orally once daily
E/C/F/TAF PlaceboDrug
Tablet administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48Time frame: Week 48
Locations
117 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Spectrum Medical Group
Phoenix, Arizona
Kaiser Permanente - Los Angeles Medical Center
Los Angeles, California
University of Southern California AIDS Clinical Trials Group
Los Angeles, California
Peter J. Ruane, Inc.
Los Angeles, California
Anthony Mills MD Inc
Los Angeles, California
Alameda County Medical Center
Oakland, California
Stanford University
Palo Alto, California
University of California, Davis Medical Center
Sacramento, California
Kaiser Permanente Medical Group
Sacramento, California
La Playa Medical Group and Clinical Research
San Diego, California
Kaiser Permanente San Francisco
San Francisco, California
Kaiser Permanente
San Leandro, California
Los Angeles Biomedical Research Institute at Harbor - UCLA Medical Center
Torrance, California
University of Colorado
Aurora, Colorado
APEX Research LLC
Denver, Colorado
Greenwich Hospital
Greenwich, Connecticut
Yale University
New Haven, Connecticut
Dupont Circle Physicians Group
Washington D.C., District of Columbia
Whitman-Walker Health
Washington D.C., District of Columbia
Capital Medical Associates, PC
Washington D.C., District of Columbia
Medical Faculty Associates
Washington D.C., District of Columbia
Gary J. Richmond,M.D.,P.A.
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
AIDS Healthcare Foundation
Miami, Florida
AIDS Healthcare Foundation
Miami Beach, Florida
Orlando Immunology Center
Orlando, Florida
Idocf/Valuhealthmd
Orlando, Florida
Infectious Diseases Associates of NW FL
Sarasota, Florida
University of South Florida
Tampa, Florida
Infectious Disease Research Institute Inc.
Tampa, Florida
St. Joseph's Comprehensive Research Institute
Tampa, Florida
Triple O Research Institute PA
West Palm Beach, Florida
AIDS Research Consortium of Atlanta
Atlanta, Georgia
Atlanta ID Group, PC
Atlanta, Georgia
Emory University
Atlanta, Georgia
Georgia Regents University
Augusta, Georgia
Infectious Disease Specialist of Atlanta
Decatur, Georgia
Mercer University
Macon, Georgia
University of Hawaii - Hawaii Center for AIDS
Honolulu, Hawaii
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.